CERETEC .5 mg/5mL (Technetium Tc-99M Exametazime INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) .5 mg/5mL

CERETEC .5 mg/5mL is a lyophilized powder for solution, used in diagnostic imaging procedures. This radiopharmaceutical contains Technetium TC-99m Exametazime, a key agent for brain imaging. Ideal for healthcare professionals seeking reliable diagnostic tools.

Strength

.5 mg/5mL

Pack Size

5 VIAL in 1 TRAY (17156-022-05) / 5 mL in 1 VIAL

Manufacturer / TM Owner

Medi-Physics Inc. dba GE Healthcare.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

CERETEC .5 mg/5mL is primarily used in diagnostic imaging to assess brain perfusion. It is often utilized in single-photon emission computed tomography (SPECT) scans. This radiopharmaceutical helps in evaluating conditions related to cerebral blood flow, providing critical insights for medical professionals.

Side Effects

When administered intravenously, CERETEC .5 mg/5mL works by binding to red blood cells, allowing for clear imaging of brain activity. The effects are typically observed through imaging techniques, aiding in the visualization of blood flow patterns in the brain.

Precautions & Warnings

Handling CERETEC .5 mg/5mL requires adherence to standard radiopharmaceutical safety protocols. It should be used under the supervision of qualified healthcare professionals. Proper disposal and storage are essential to ensure safety and efficacy.

Avoid Interactions

CERETEC .5 mg/5mL may interact with other radiopharmaceuticals or medications that affect blood flow or imaging results. It is important to consult with a healthcare provider to understand potential interactions and ensure safe usage.

Frequently Asked Questions

CERETEC .5 mg/5mL is used in diagnostic imaging to assess brain perfusion, often in SPECT scans.

CERETEC .5 mg/5mL is administered intravenously as a solution prepared from the lyophilized powder.

The effects of CERETEC .5 mg/5mL are observed through imaging techniques, aiding in the visualization of brain blood flow.

Yes, it should be handled and administered by qualified healthcare professionals following radiopharmaceutical safety protocols.

Potential interactions with other radiopharmaceuticals or medications affecting blood flow should be discussed with a healthcare provider.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.